WinstonWınston
Boule Diagnostics AB logo

Boule Diagnostics AB

BOUL.ST
24
Medical - Specialties · Healthcare
Price
kr 3.45
-0.30 (-8.00%)
Market Cap
kr 134.0M
Exchange
Stockholm Stock Exchange
Winston Score
24
Winston is worried
Weak fundamentals across most pillars.

Share count rising — dilution

+34.9% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 28.2M (2021) → 38.0M (2025)

Boule Diagnostics is a Swedish medical device company that makes blood analysis machines and the test supplies that go with them. Their instruments count and measure the different types of cells in a blood sample — a common test used in hospitals and clinics to diagnose infections, anemia, and other conditions. Boule focuses on smaller, affordable analyzers designed for clinics and labs in emerging markets like Africa, Latin America, and parts of Asia.

The company earns money by selling both the machines and the consumable reagents — the chemical liquids needed to run each test — which creates a recurring revenue stream after the initial instrument sale. Boule operates globally but generates a significant share of revenue outside wealthy Western markets, where low-cost, easy-to-use devices have a competitive edge. The negative ROIC signals the business is currently struggling to generate returns above its cost of capital, and the key challenge ahead is scaling volume in developing markets while keeping costs under control.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-10.0% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-40.7% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$59M/ year

Declining (-81% vs prior year)

12.0% of revenue

Below sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

25.7%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Position

Cash flow positive

$19M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Revenue declining

Boule Diagnostics AB's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
41.5%
Healthy — 41.5% gross margin
Operating Margin
-1.4%
Losing money on operations — -1.4%
ROCE
-0.4%
Weak — -0.4% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
-8.6%
Shrinking sales (-8.6% YoY)
EPS YoY
N/A
Data not available
EPS Consistency
4/8 quarters
Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
N/A
Data not available
FCF Margin
3.4%
Thin free cash flow (3.4%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
1.05
Elevated debt (1.05)
Interest Cover
1.11x
Dangerous — barely covers interest (1.1x)

Interest coverage between 1 and 3. Profits cover interest, but with little room to spare.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial